Cisplatin liposomal inhaled - Eleison Pharmaceuticals

Drug Profile

Cisplatin liposomal inhaled - Eleison Pharmaceuticals

Alternative Names: ILC; Inhaled cisplatin - Insmed; Inhaled lipid cisplatin; Inhaled lipid-complexed cisplatin (ILC); Lipid cisplatin complex

Latest Information Update: 21 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Insmed
  • Developer Eleison Pharmaceuticals
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer metastases; Osteosarcoma

Most Recent Events

  • 11 Dec 2015 Eleison receives patent allowance for lipid-complexed cisplatin United States
  • 24 Jun 2015 Cisplatin liposomal inhaled is still in phase II trials for Osteosarcoma with Cancer metastases (In adolescents, Prevention of relapse, Second-line therapy or greater) in the USA
  • 19 Jan 2015 Inhaled liposomal cisplatin sub-licensed to Intelgen in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top